BRPI0406801A - Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes - Google Patents

Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes

Info

Publication number
BRPI0406801A
BRPI0406801A BR0406801-7A BRPI0406801A BRPI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A BR PI0406801 A BRPI0406801 A BR PI0406801A
Authority
BR
Brazil
Prior art keywords
thieno
autoimmune diseases
sup
pyrimidinedione derivatives
modulating autoimmune
Prior art date
Application number
BR0406801-7A
Other languages
English (en)
Inventor
Simon David Guile
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0406801A publication Critical patent/BRPI0406801A/pt
Publication of BRPI0406801B1 publication Critical patent/BRPI0406801B1/pt
Publication of BRPI0406801B8 publication Critical patent/BRPI0406801B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

"DERIVADOS DE TIENO-PIRIMIDINODIONA E USO DOS MESMOS NA MODULAçãO DE DOENçAS AUTOIMUNES". A presente invenção se refere a derivados de tieno-pirimidinodiona de fórmula (1): em que R¬ 1¬ e R¬ 2¬ independentemente entre si, representam um grupo C~ 1-6~alquila, C~ 3-6~alquenila, C~ 3-5~cicloalquil-C~ 1-3~alquila ou C~ 3-6~cicloalquila; cada um dos quais podendo ser opcionalmente substituído por 1 a 3 átomos de halogênio; R¬ 3¬ é um grupo- CO-G ou SO~ 2~-G, onde G é um anel de 5 ou 6 membros contendo um átomo de nitrogênio e um segundo heteroátomo selecionado de oxigênio e enxofre adjacente ao nitrogênio; o anel sendo substituído por pelo menos um grupo conforme definido no relatório descritivo; Q é CR¬ 4¬R¬ 5¬, onde R¬ 4¬ é hidrogênio, flúor ou C~ 1-6~ alquila e R¬ 5¬ é hidrogênio, flúor ou hidróxi; e Ar é um sistema de anel aromático de 5 a 10 membros, em que até 4 átomos do anel podem ser heteroátomos, independentemente selecionados de nitrogênio, oxigênio e enxofre, o sistema de anel sendo opcionalmente substituído por um ou mais grupos definidos no presente relatório descritivo; assim como sais e solvatos farmaceuticamente aceitáveis do mesmo. São também descritos processos para a preparação de tais compostos, composições farmacêuticas contendo os mesmos e seu uso em procedimentos de terapia, particularmente, na terapia de imunossupressão.
BRPI0406801A 2003-01-17 2004-01-15 derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes BRPI0406801B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300119A SE0300119D0 (sv) 2003-01-17 2003-01-17 Novel compounds
SE0300119-5 2003-01-17
PCT/SE2004/000052 WO2004065394A1 (en) 2003-01-17 2004-01-15 Thienopyrimidinediones and their use in the modulation of autoimmune disease

Publications (3)

Publication Number Publication Date
BRPI0406801A true BRPI0406801A (pt) 2006-01-17
BRPI0406801B1 BRPI0406801B1 (pt) 2018-04-03
BRPI0406801B8 BRPI0406801B8 (pt) 2021-05-25

Family

ID=20290154

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406801A BRPI0406801B8 (pt) 2003-01-17 2004-01-15 derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes

Country Status (24)

Country Link
US (2) US7384951B2 (pt)
EP (1) EP1587812B1 (pt)
JP (1) JP4519121B2 (pt)
KR (2) KR20110125256A (pt)
CN (1) CN100334093C (pt)
AT (1) ATE335748T1 (pt)
AU (1) AU2004206012B2 (pt)
BR (1) BRPI0406801B8 (pt)
CA (1) CA2512441C (pt)
DE (1) DE602004001857T2 (pt)
EG (1) EG25613A (pt)
ES (1) ES2270337T3 (pt)
HK (1) HK1081959A1 (pt)
IL (1) IL169370A (pt)
IS (1) IS2376B (pt)
MX (1) MXPA05007496A (pt)
NO (1) NO333702B1 (pt)
NZ (1) NZ541217A (pt)
PL (1) PL214682B1 (pt)
RU (1) RU2331647C2 (pt)
SE (1) SE0300119D0 (pt)
UA (1) UA81788C2 (pt)
WO (1) WO2004065394A1 (pt)
ZA (1) ZA200505364B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
NZ541218A (en) * 2003-01-17 2008-05-30 Astrazeneca Ab Thienopyrimidinediones and their use in modulation of autoimmune disease
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
KR20080027775A (ko) 2005-05-17 2008-03-28 플렉시콘, 인코퍼레이티드 피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008080001A2 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
SG184767A1 (en) * 2009-03-23 2012-10-30 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
SG174403A1 (en) * 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
CR20170089A (es) 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2013109972A2 (en) 2012-01-20 2013-07-25 Regents Of The University Of Minnesota Therapeutic compounds
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
AU2014340249B2 (en) * 2013-10-21 2017-05-25 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
JP6725519B2 (ja) * 2015-01-22 2020-07-22 ザ スクリプス リサーチ インスティテュート 複素環式のモノカルボン酸トランスポータ阻害薬
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
KR101730536B1 (ko) * 2016-03-17 2017-05-02 주식회사 골프존 스크린 골프 시스템에서 구현되는 컨텐츠 전송 서비스 방법, 컨텐츠 전송 서비스를 위한 모바일 단말기의 제어방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록매체
KR101712836B1 (ko) * 2016-03-17 2017-03-22 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
KR101712838B1 (ko) * 2016-03-17 2017-03-07 주식회사 골프존 가상 골프 시뮬레이션 장치, 가상 골프를 위한 영상 구현 방법 및 이를 기록한 컴퓨팅 장치에 의해 판독 가능한 기록 매체
TWI823932B (zh) 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US738495A (en) * 1902-12-26 1903-09-08 William E Sherwood Thill-coupling.
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
TR200001603T2 (tr) 1997-12-05 2000-10-23 Astrazeneca Uk Limited Yeni bileşikler
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000012514A1 (en) * 1998-08-28 2000-03-09 Astrazeneca Ab Novel compounds
EP1280806B1 (en) * 2000-05-04 2004-08-04 AstraZeneca AB THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
NZ541218A (en) 2003-01-17 2008-05-30 Astrazeneca Ab Thienopyrimidinediones and their use in modulation of autoimmune disease
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
UA81788C2 (uk) 2008-02-11
BRPI0406801B8 (pt) 2021-05-25
DE602004001857D1 (de) 2006-09-21
US20060052400A1 (en) 2006-03-09
MXPA05007496A (es) 2005-09-21
EP1587812B1 (en) 2006-08-09
PL214682B1 (pl) 2013-09-30
US7384951B2 (en) 2008-06-10
NZ541217A (en) 2008-05-30
PL378222A1 (pl) 2006-03-20
AU2004206012B2 (en) 2007-06-14
CN1761672A (zh) 2006-04-19
ES2270337T3 (es) 2007-04-01
RU2331647C2 (ru) 2008-08-20
CA2512441A1 (en) 2004-08-05
IL169370A (en) 2011-05-31
RU2005121494A (ru) 2006-02-10
KR20050092760A (ko) 2005-09-22
CA2512441C (en) 2012-01-03
NO20053826L (no) 2005-10-17
KR101107486B1 (ko) 2012-01-19
KR20110125256A (ko) 2011-11-18
JP4519121B2 (ja) 2010-08-04
WO2004065394A1 (en) 2004-08-05
ZA200505364B (en) 2006-09-27
US20080214579A1 (en) 2008-09-04
IS7965A (is) 2005-07-29
SE0300119D0 (sv) 2003-01-17
NO333702B1 (no) 2013-08-26
AU2004206012A1 (en) 2004-08-05
CN100334093C (zh) 2007-08-29
EP1587812A1 (en) 2005-10-26
JP2006516974A (ja) 2006-07-13
HK1081959A1 (en) 2006-05-26
BRPI0406801B1 (pt) 2018-04-03
IL169370A0 (en) 2007-07-04
EG25613A (en) 2012-03-22
ATE335748T1 (de) 2006-09-15
DE602004001857T2 (de) 2007-05-24
IS2376B (is) 2008-07-15
NO20053826D0 (no) 2005-08-15

Similar Documents

Publication Publication Date Title
BRPI0406801A (pt) Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
IS6520A (is) Ný efnasambönd
IS6658A (is) Ný efnasambönd
SE9902987D0 (sv) Novel compounds
EA200401526A1 (ru) Новые соединения и их применение
SE0302139D0 (sv) Novel compounds
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
TW200613243A (en) Novel compounds
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
ATE316083T1 (de) Adamantanderivate
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
SE0402925D0 (sv) Novel Compounds
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE0101038D0 (sv) Novel compounds
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
SE0303280D0 (sv) Novel compounds
SE0401763D0 (sv) Compounds
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
SE0302755D0 (sv) Novel compounds
SE0202693D0 (sv) Compounds
ATE274515T1 (de) Pyrazolopyridinderivate
SE0403118D0 (sv) New compounds 2
MXPA05007495A (es) Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
SE0403117D0 (sv) New compounds 1
SE0002330D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.